111 Capital Apellis Pharmaceuticals, Inc. Transaction History
111 Capital
- $518 Billion
- Q1 2025
A detailed history of 111 Capital transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, 111 Capital holds 16,836 shares of APLS stock, worth $293,619. This represents 0.07% of its overall portfolio holdings.
Number of Shares
16,836Holding current value
$293,619% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$215 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$213 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$207 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$177 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$168 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $1.92B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...